NKGen Biotech increases loan principal by $251,000 under amended agreement

NKGen Biotech, Inc. and its subsidiary NKGen Operating Biotech, Inc. entered into a third amendment to a secured promissory note with AlpineBrook Capital GP I Limited on January 30, 2026, to secure an additional $251,000 in funding. This financial agreement, disclosed via an SEC filing, increases the total principal amount of the note to $26,758,106. The amendment was executed to provide the company with immediate liquidity, with interest on the newly provided funds beginning to accrue from the date of the funding. This latest transaction follows a series of rapid financial adjustments for the biotech firm, which is traded on the OTC Expert Market. The original promissory note was established on January 5, 2026, and has since undergone multiple revisions, including amendments on January 12 and a subsequent second amendment. These frequent updates highlight the company's active efforts to manage its debt structure and capital flow as it navigates the biotechnology sector. Beyond this specific loan increase, NKGen Biotech has been aggressively pursuing a strategy of expansion and scientific enhancement. The company previously utilized its credit facilities with AlpineBrook Capital to acquire a majority stake in NKGen Biotech Korea Co., Ltd. Additionally, the firm recently bolstered its leadership by appointing Dr. Bruce L. Miller, a prominent neurology expert from the University of California, San Francisco, to its Scientific Advisory Board to guide its research initiatives.